Zacks Investment Research downgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a sell rating in a research report report published on Friday.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
VYGR has been the topic of several other research reports. Stifel Nicolaus reaffirmed a buy rating and issued a $31.00 target price (up previously from $20.00) on shares of Voyager Therapeutics in a report on Monday, October 23rd. Canaccord Genuity reaffirmed a buy rating and issued a $26.00 target price on shares of Voyager Therapeutics in a report on Tuesday, January 23rd. Raymond James Financial began coverage on shares of Voyager Therapeutics in a report on Thursday, October 12th. They issued an outperform rating and a $35.00 target price on the stock. BidaskClub upgraded shares of Voyager Therapeutics from a hold rating to a buy rating in a research note on Friday, January 5th. Finally, Robert W. Baird began coverage on shares of Voyager Therapeutics in a research note on Monday, October 30th. They issued an outperform rating and a $31.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have given a buy rating to the company. Voyager Therapeutics has an average rating of Buy and an average target price of $26.90.
Shares of Voyager Therapeutics (VYGR) opened at $18.40 on Friday. The firm has a market cap of $495.87 and a P/E ratio of -6.48. Voyager Therapeutics has a 1-year low of $8.10 and a 1-year high of $25.99.
In other Voyager Therapeutics news, insider Bernard Ravina sold 5,490 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $13.26, for a total value of $72,797.40. Following the transaction, the insider now directly owns 16,473 shares in the company, valued at $218,431.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 14,610 shares of company stock worth $207,158 over the last quarter. 8.00% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN grew its position in shares of Voyager Therapeutics by 312.8% during the third quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock worth $7,766,000 after acquiring an additional 285,806 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Voyager Therapeutics by 20.9% during the second quarter. Bank of New York Mellon Corp now owns 53,225 shares of the company’s stock worth $477,000 after acquiring an additional 9,207 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Voyager Therapeutics by 3.2% during the second quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after acquiring an additional 13,194 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Voyager Therapeutics during the third quarter worth approximately $5,155,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Voyager Therapeutics during the third quarter worth approximately $2,695,000. Institutional investors and hedge funds own 36.18% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.